Основные параметры
P/S |
177.06 |
P/BV |
22.13 |
EV/EBITDA |
-19.06 |
EBITDA |
-0.05 |
Цена ао |
21.02 |
Оценка
|
Недооценка
Название |
Значение |
Оценка |
P/S |
177.06 |
1 |
P/BV |
22.13 |
1 |
P/E |
|
0 |
EV/EBITDA |
-19.06 |
10 |
|
|
|
|
Эффективность
Название |
Значение |
Оценка |
ROA, % |
-27.72 |
1 |
ROE, % |
-90.46 |
1 |
|
|
|
|
|
Дивиденды
Название |
Значение |
Оценка |
Div yield, % |
|
0 |
DSI |
0 |
0 |
|
|
|
|
Долг
Название |
Значение |
Оценка |
Долг/EBITDA |
|
0 |
|
|
|
|
Импульс роста
Название |
Значение |
Оценка |
Рост прибыли, % |
41.42 |
8 |
Рост цены акции, % |
-89.28 |
0 |
Рост дивидендов, % |
0 |
0 |
|
|
|
|
Основные владельцы
Institutions |
Объем |
Доля, % |
Alambic Investment Management, L.P. |
59766 |
0.12 |
AdvisorShares Investments, LLC |
2600 |
0.01 |
Samsara BioCapital, LLC |
2153265 |
4.26 |
Telemetry Investments, L.L.C. |
267466 |
0.53 |
Foresite Capital Management III, LLC |
684912 |
1.36 |
Parkman Healthcare Partners LLC |
1842661 |
3.65 |
Endurant Capital Management LP |
1432817 |
2.84 |
SEI Investments Management Corp |
141371 |
0.28 |
BMO Global Asset Management |
75944 |
0.15 |
Aisling Capital Management LP |
634455 |
1.26 |
Sofinnova Ventures |
1911573 |
3.78 |
EcoR1 Capital, LLC |
1531312 |
3.03 |
BlackRock Fund Advisors |
1353400 |
2.68 |
Vivo Capital, LLC |
1647214 |
3.26 |
Rock Springs Capital Management LP |
2076307 |
4.11 |
LoCorr Fund Management, LLC |
3773 |
0.01 |
M & G Investment Management |
40645 |
0.08 |
Invesco Capital Management LLC |
121038 |
0.24 |
The Variable Annuity Life Insurance Company |
119846 |
0.24 |
Foresite Capital Management IV, LLC |
144874 |
0.29 |
Содержится в ETF
Похожие компании
Описание Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK\u002FTXK\u002FJAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.